Dr. Reddys Labs (RDY) Reports Q2 EPS of $0.27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Dr. Reddy’s Q2 and H1 FY17 Financial Results
October 25, 2016 6:37 AM EDT
Q2 Revenues at Rs. 35.9 Bn
(QoQ growth: 11%)
Q2 EBITDA at Rs. 6.4 Bn
(17.9% of Revenues)
H1 Revenues at Rs. 68.2 Bn
(YoY decline: 12%)
H1 EBITDA at Rs. 10.4 Bn
(15.2% of Revenues)
HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddys Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the second quarter and half year ended September 30, 2016 under International Financial Reporting Standards (IFRS).
Q2 FY17: Key Highlights
Revenues at Rs. 35.9 billion: QoQ growth: 11%... More